Usage : Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of COVID-19 at high risk of developing severe disease.
Therapeutic Use : Treatment of mild to moderate coronavirus disease (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness